King Pharmaceuticals signed an agreement worth US$935 M with Elan to acquire Elan’s primary care business unit in US and Puerto Rico. The deal includes branded pharmaceutical products, Sonata® (zaleplon) for treating insomnia and Skelaxin® (metaxolone), muscle relaxant.